Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Overview of Key Overnight Developments on June 28

Overview of Key Overnight Developments on June 28

金色财经金色财经2024/06/27 23:51
Show original

21:00-7:00 Keywords: Bolivia, VanEck, Solana, Coinbase

1. Federal Reserve Governor Bowman: It is not appropriate to cut interest rates now;

2. Worldcoin's World ID will be launched on Solana;

3. Bolivia lifts ban on Bitcoin and crypto payments;

4. VanEck has submitted Solana Trust application documents to the US SEC;

5. 21Shares submits 8-A12B documents for its spot Ethereum ETF;

6. US SEC Chairman expects spot Ethereum ETF to be listed as early as September;

7. A proposed Bitcoin and gold combined ETF may be launched on September 9;

8. Coinbase and Stripe establish partnership to expand global adoption of cryptocurrency;

9. Biden campaign team hires Coinbase advisory board member as advisor for the 2024 election;

10. Galaxy Digital: Expects $7.5 billion inflow into spot Ethereum ETF within the first five months;

11. Bloomberg analyst: VanEck's Solana Trust application document is just an S-1 filing, making it impossible to determine the deadline.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%